Video Experimental Relacionado
Updated: Feb 17, 2026
09:38
Determining Pain Detection and Tolerance Thresholds Using an Integrated, Multi-Modal Pain Task Battery
Published on: April 14, 2016
13.2K
Desarrollo de un modelo de madurez de políticas para terapéuticas digitales recetadas basado en el consenso de
João Rocha-Gomes1, Bernardo Sousa-Pinto2, Ana Luisa Neves2,3
1Faculty of Medicine, Department of Community Medicine, Health Information and Decision, University of Porto, Porto, Portugal jngomes@med.up.pt.
BMJ open
|February 15, 2026
Resumen
Este estudio desarrolla un marco de madurez de políticas para evaluar la preparación de las terapéuticas digitales recetadas (PDTx). El estudio eDelphi tiene como objetivo guiar la adopción consistente de estas soluciones de salud basadas en software.
Área de la Ciencia:
- Salud Digital
- Política Sanitaria
- Innovación Sanitaria
Sus antecedentes:
- Las terapéuticas digitales recetadas (PDTx) ofrecen soluciones de tratamiento novedosas pero se enfrentan a paisajes políticos fragmentados.
- Las variaciones en la regulación, el reembolso y la integración crean incertidumbres de adopción para las partes interesadas.
- Se necesita un enfoque sistemático para evaluar la preparación nacional o regional para las PDTx.
Objetivo del estudio:
- Desarrollar y validar un marco integral de madurez de políticas para evaluar la preparación para la adopción de PDTx.
- Guiar a los responsables políticos, desarrolladores y proveedores para navegar por las complejidades de la implementación de PDTx.
- Establecer una herramienta impulsada por el consenso para la evaluación comparativa y el avance de la integración de PDTx en los sistemas de salud.
Principales métodos:
- Un estudio e-Delphi que involucra hasta tres rondas con expertos diversos de seis grupos de partes interesadas.
- Muestreo intencional que prioriza a expertos europeos, con potencial para perspectivas internacionales más amplias.
- Utilización de una escala Likert de 5 puntos para datos cuantitativos y preguntas de texto abierto para información cualitativa, con un consenso definido como un acuerdo de ≥70%.
Principales resultados:
- El protocolo del estudio describe el refinamiento iterativo y la validación de un marco de madurez de políticas de PDTx.
- Se alcanzará un consenso sobre los dominios del marco, los criterios de puntuación y los umbrales de madurez.
- El marco validado capturará elementos esenciales para el desarrollo e implementación de políticas de PDTx.
Conclusiones:
- El marco desarrollado proporcionará una referencia para evaluar y avanzar en la adopción de PDTx.
- Tiene como objetivo reducir las incertidumbres y fomentar un desarrollo de políticas coherente en todas las jurisdicciones.
- La difusión a través de publicaciones y resúmenes de políticas apoyará la gobernanza de la salud digital.
Videos de Conceptos Relacionados
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
17
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
17
01:29Pharmacodynamic Models: Direct Effect Model and Indirect Response Model
17
Pharmacodynamic models are essential tools in understanding the relationship between drug concentrations and their effects on biological systems. By characterizing the dynamics of drug action, these models guide dose selection, optimize therapeutic efficacy, and inform the development of new drugs. Two major classes of pharmacodynamic models include direct effect and indirect response models.Direct Effect ModelsDirect effect models describe the immediate relationship between drug concentration...
17
01:27Pharmacodynamic Models: Overview
19
Pharmacodynamic (PD) responses describe the interaction between a drug and its biological target, culminating in a physiological effect. These responses can be classified into different types: continuous variables, such as blood glucose levels; categorical outcomes, like survival rates; and time-to-event metrics, such as disease progression. Understanding and modeling PD responses are critical for optimizing drug efficacy and safety.PD models describe the relationship between drug concentration...
19
01:26Drug Administration and Therapy Phases: Overview
1.5K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.5K
01:24Pharmacokinetic–Pharmacodynamic Relationship: Problems
18
The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...
18
01:15Pharmacodynamic Models: Linear Concentration–Effect Model
20
The linear concentration–effect model, underpinned by the principle that pharmacological effect (E) is directly proportional to plasma drug concentration (C), emerges as a pivotal simplification of the Emax model for conditions where C is significantly less than EC50. This model portrays a linear trajectory of the concentration–effect relationship when drug levels are markedly below the EC50 threshold.Despite its inherent assumption of continuous effect augmentation with increasing...
20